Greg Hurlbut

Co-Founder and SVP Head of Research, Sionna Therapeutics

Boston, Massachusetts

About

Male

Greg Hurlbut is the Co-Founder and SVP Head of Research of Sionna Therapeutics. He previously worked at Sanofi Genzyme as a Head of Protein Conformational Diseases Research. Greg Hurlbut attended the University of Paris-Sud.

Experience

Sionna Therapeutics

Co-Founder and SVP Head of Research

View →

Growth62Natick, Massachusetts, United StatesBiotech/Pharma · Biotechnology

Education

University of Paris-Saclay · Ph.D., Cell and Molecular Biology
2000 – 2006
University of Massachusetts Amherst · BS, Biology

Headlines from Google News. Social posts load from the platform only when you open a tab.

Sionna Therapeutics Reports First Quarter 2026 Financial Results
Yahoo Finance · May 12
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
manilatimes.net · Oct 25
SION Stock Price and Chart — NASDAQ:SION
TradingView · Oct 12
Sionna's experimental CFTR modulators show promise in preclinical tests
Cystic Fibrosis News Today · Jun 12
Vertex Pharma Challenger Sionna Secures $191M in IPO Cash for Cystic Fibrosis Pipeline
MedCity News · Feb 9

People at Sionna Therapeutics

Mark Munson

Co-Founder and Vice President of Medicinal Chemistry

Michael Cloonan

President and Chief Executive Officer

Bruce Booth

Data from: crunchbase